{"title":"hplc -MS/MS法测定人血浆中达格列净及其主要代谢物的含量","authors":"Zhijun Liu, Yanru Liu, Zhipeng Wang, Huiping Lu, Xiujing Zhu, Yuxi Bao, Bingyan Cai, Shouhong Gao, Xia Tao, Deduo Xu","doi":"10.1093/chromsci/bmaf019","DOIUrl":null,"url":null,"abstract":"<p><p>Dapagliflozin (DAPA), an inhibitor of sodium-dependent glucose cotransporter-2, has been created to treat individuals with type 2 diabetes mellitus. A method was developed and validated using high-performance liquid chromatography coupled to tandem mass spectrometry to aid in studying the connection between clinical effectiveness and concentration of DAPA and its primary metabolite dapagliflozin 3-O-glucuronide (D3OG) in human plasma. The two analytes were separated using the Waters XSELECT HSS T3 (2.1 × 100 mm, 3.5 μm; Waters Co., Milford, USA) chromatographic column, with a mobile phase flow rate of 0.3 mL/min. The elution program was performed after protein precipitation with methanol, which only required a 5-min duration. The extraction recovery was from 99.8 to 109% for DAPA and from 101 to 103% for D3OG. Validation of the method for detecting DAPA within the range of 5-50 ng/mL and D3OG within the range of 50-500 ng/mL demonstrated satisfactory inter- and intra-day precision and accuracy. The method was successfully developed and validated, and it was used to measure the levels of DAPA and D3OG in plasma samples from patients with type 2 diabetes mellitus.</p>","PeriodicalId":15430,"journal":{"name":"Journal of chromatographic science","volume":"63 4","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Simple and Sensitive LC-MS/MS Method for Determination of Dapagliflozin and Its Major Metabolite in Human Plasma.\",\"authors\":\"Zhijun Liu, Yanru Liu, Zhipeng Wang, Huiping Lu, Xiujing Zhu, Yuxi Bao, Bingyan Cai, Shouhong Gao, Xia Tao, Deduo Xu\",\"doi\":\"10.1093/chromsci/bmaf019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dapagliflozin (DAPA), an inhibitor of sodium-dependent glucose cotransporter-2, has been created to treat individuals with type 2 diabetes mellitus. A method was developed and validated using high-performance liquid chromatography coupled to tandem mass spectrometry to aid in studying the connection between clinical effectiveness and concentration of DAPA and its primary metabolite dapagliflozin 3-O-glucuronide (D3OG) in human plasma. The two analytes were separated using the Waters XSELECT HSS T3 (2.1 × 100 mm, 3.5 μm; Waters Co., Milford, USA) chromatographic column, with a mobile phase flow rate of 0.3 mL/min. The elution program was performed after protein precipitation with methanol, which only required a 5-min duration. The extraction recovery was from 99.8 to 109% for DAPA and from 101 to 103% for D3OG. Validation of the method for detecting DAPA within the range of 5-50 ng/mL and D3OG within the range of 50-500 ng/mL demonstrated satisfactory inter- and intra-day precision and accuracy. The method was successfully developed and validated, and it was used to measure the levels of DAPA and D3OG in plasma samples from patients with type 2 diabetes mellitus.</p>\",\"PeriodicalId\":15430,\"journal\":{\"name\":\"Journal of chromatographic science\",\"volume\":\"63 4\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of chromatographic science\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1093/chromsci/bmaf019\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of chromatographic science","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1093/chromsci/bmaf019","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
A Simple and Sensitive LC-MS/MS Method for Determination of Dapagliflozin and Its Major Metabolite in Human Plasma.
Dapagliflozin (DAPA), an inhibitor of sodium-dependent glucose cotransporter-2, has been created to treat individuals with type 2 diabetes mellitus. A method was developed and validated using high-performance liquid chromatography coupled to tandem mass spectrometry to aid in studying the connection between clinical effectiveness and concentration of DAPA and its primary metabolite dapagliflozin 3-O-glucuronide (D3OG) in human plasma. The two analytes were separated using the Waters XSELECT HSS T3 (2.1 × 100 mm, 3.5 μm; Waters Co., Milford, USA) chromatographic column, with a mobile phase flow rate of 0.3 mL/min. The elution program was performed after protein precipitation with methanol, which only required a 5-min duration. The extraction recovery was from 99.8 to 109% for DAPA and from 101 to 103% for D3OG. Validation of the method for detecting DAPA within the range of 5-50 ng/mL and D3OG within the range of 50-500 ng/mL demonstrated satisfactory inter- and intra-day precision and accuracy. The method was successfully developed and validated, and it was used to measure the levels of DAPA and D3OG in plasma samples from patients with type 2 diabetes mellitus.
期刊介绍:
The Journal of Chromatographic Science is devoted to the dissemination of information concerning all methods of chromatographic analysis. The standard manuscript is a description of recent original research that covers any or all phases of a specific separation problem, principle, or method. Manuscripts which have a high degree of novelty and fundamental significance to the field of separation science are particularly encouraged. It is expected the authors will clearly state in the Introduction how their method compares in some markedly new and improved way to previous published related methods. Analytical performance characteristics of new methods including sensitivity, tested limits of detection or quantification, accuracy, precision, and specificity should be provided. Manuscripts which describe a straightforward extension of a known analytical method or an application to a previously analyzed and/or uncomplicated sample matrix will not normally be reviewed favorably. Manuscripts in which mass spectrometry is the dominant analytical method and chromatography is of marked secondary importance may be declined.